Inventor · disambiguated record
Benjamin Bader
Also filed as: BADER BENJAMIN
28 granted patents·23 pending applications·131 citations·filing 2005–2023
95Inventor score
Top patents by PatentIndex Score
51 records- 0196US9549932B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2016·Granted Jan 24, 2017·26 cites·30 claims
- 0293US10729680B25-substituted 2-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2017·Granted Aug 4, 2020·10 cites·14 claims
- 0391US11795164B22-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancerBAYER AG·Filed 2022·Granted Oct 24, 2023·3 cites·8 claims
- 0490US7977325B23-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agentsBAYER SCHERING PHARMA AG·Filed 2005·Granted Jul 12, 2011·31 cites·15 claims
- 0589US9993484B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2015·Granted Jun 12, 2018·4 cites·9 claims
- 0688US11998539B2Substituted aminoquinolones as DGKalpha inhibitors for immune activationBAYER AG·Filed 2022·Granted Jun 4, 2024·1 cites·24 claims
- 0788US7750000B2Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicamentsBAYER SCHERING PHARMA AG·Filed 2006·Granted Jul 6, 2010·24 cites·2 claims
- 0885US11529356B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2020·Granted Dec 20, 2022·1 cites·20 claims
- 0985US10772893B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2018·Granted Sep 15, 2020·2 cites·12 claims
- 1081US9340528B2Substituted aminoquinoxalines as tyrosine threonine kinase inhibitorsBADER BENJAMIN·Filed 2010·Granted May 17, 2016·12 cites·6 claims
- 1180US9670202B2Substituted triazolopyridinesBayer Pharma AG·Filed 2014·Granted Jun 6, 2017·2 cites·16 claims
- 1278US11304946B22-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonistsBAYER AG·Filed 2018·Granted Apr 19, 2022·2 cites·11 claims
- 1376US8653076B2Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticalsPRIEN OLAF·Filed 2007·Granted Feb 18, 2014·5 cites·17 claims
- 1475US11964953B2Substituted aminothiazoles as DGKzeta inhibitors for immune activationBAYER AG·Filed 2022·Granted Apr 23, 2024·0 cites·26 claims
- 1573US11459312B2Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamidesBAYER AG·Filed 2018·Granted Oct 4, 2022·2 cites·12 claims
- 1668US11524944B22-phenylpyrimidine-4-carboxamides as AHR inhibitorsBAYER AG·Filed 2018·Granted Dec 13, 2022·1 cites·11 claims
- 1766US9199999B2Substituted imidazopyrazinesKLAR ULRICH·Filed 2011·Granted Dec 1, 2015·1 cites·5 claims
- 1865US9284317B2Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitorsKOPPITZ MARCUS·Filed 2011·Granted Mar 15, 2016·1 cites·10 claims
- 1965US9212184B26-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitorsKOPPITZ MARCUS·Filed 2011·Granted Dec 15, 2015·1 cites·10 claims
- 2063US8551980B2Substituted triazolopyridinesSCHULZE VOLKER·Filed 2010·Granted Oct 8, 2013·1 cites·13 claims
- 2162US2023167078A1Substituted aminothiazoles as dgkzeta inhibitors for immune activationBAYER AG·Filed 2021·Application pending·0 cites
- 2261US8729082B2Substituted imidazoquinoxalinesKOPPITZ MARCUS·Filed 2010·Granted May 20, 2014·1 cites·13 claims
- 2360US2023167103A1Substituted aminothiazoles as dgkzeta inhibitors for immune activationBAYER AG·Filed 2021·Application pending·0 cites
- 2458US2025154170A1Fused pyrimidines as kras inhibitorsBAYER AG·Filed 2023·Application pending·0 cites
- 2557US12478621B2Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Granted Nov 25, 2025·0 cites·17 claims
- 2657US2024247015A1Phosphorus derivatives as novel sos1 inhibitorsBAYER AG·Filed 2022·Application pending·0 cites
- 2753US2022235013A12-methyl-quinazolinesBayer Pharma AG·Filed 2018·Application pending·0 cites
- 2853US2023357239A1Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitorsBAYER AG·Filed 2021·Application pending·0 cites
- 2951US2014135323A1Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticalsBAYER IP GMBH·Filed 2014·Application pending·0 cites
- 3049US2011071125A1Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activityRUDOLPH JOACHIM·Filed 2008·Application pending·0 cites
- 3148US2023113037A1[1,2,4]triazolo[1,5-c]quinazolin-5-aminesBAYER AG·Filed 2020·Application pending·0 cites
- 3248US2022227729A1Identification and use of kras inhibitorsBAYER AG·Filed 2020·Application pending·0 cites
- 3347US9682995B2Amino-substituted isothiazolesBayer Pharma AG·Filed 2014·Granted Jun 20, 2017·0 cites·15 claims
- 3444US2016207928A1Novel compounds for the treatment of cancerBayer Pharma AG·Filed 2014·Application pending·0 cites
- 3543US2016272635A1Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinasesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 3642US2007191393A1Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinasesLUCKING ULRICH·Filed 2007·Application pending·0 cites
- 3742US2020085791A1[(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanonesBayer Pharma AG·Filed 2017·Application pending·0 cites
- 3842US2021047297A14-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disordersBayer Pharma AG·Filed 2019·Application pending·0 cites
- 3940US10894784B2Heteroarylbenzimidazole compoundsBayer Pharma AG·Filed 2016·Granted Jan 19, 2021·0 cites·15 claims
- 4040US2006167035A1Quinoline derivative, its use, production and pharmaceutical agents containing the latterSCHWEDE WOLFGANG·Filed 2005·Application pending·0 cites
- 4139US2013303532A1Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disordersKOPPITZ MARCUS·Filed 2011·Application pending·0 cites
- 4238US2014187548A16 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersKOPPITZ MARCUS·Filed 2011·Application pending·0 cites
- 4338US2014135319A16-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersKOPPITZ MARCUS·Filed 2011·Application pending·0 cites
- 4437US9468642B2ImidazopyrazinesKLAR ULRICH·Filed 2011·Granted Oct 18, 2016·0 cites·16 claims
- 4537US2008027059A1Substituted isoxazolines, pharmaceutical compositions containing same, methods of preparing same, and uses of sameBRITTAIN DOMINIC E·Filed 2007·Application pending·0 cites
- 4637US2020079758A1[4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanonesBayer Pharma AG·Filed 2017·Application pending·0 cites
- 4736US9428460B2N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal productsBayer Pharma AG·Filed 2013·Granted Aug 30, 2016·0 cites·23 claims
- 4835US2020087284A1[4-(phenylsulfonyl)piperazin-1-yl](1h-1, 2, 3-triazol-4-yl)methanonesBayer Pharma AG·Filed 2017·Application pending·0 cites
- 4934US9676766B2TriazolopyridinesSCHULZE VOLKER·Filed 2010·Granted Jun 13, 2017·0 cites·14 claims
- 5034US9555022B2Substituted triazolopyridinesSCHULZE VOLKER·Filed 2011·Granted Jan 31, 2017·0 cites·15 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Benjamin Bader files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →